Binnopharm Group, a Russian pharmaceutical company, has ambitious plans to expand its portfolio of registered drugs as it sets its sights on entering the markets of the Eurasian Economic Union (EAEU) and CIS countries. In 2022, the company successfully conducted two clinical trials (CT) and obtained registration certificates for its developments. Looking ahead to 2023, the company has an exciting lineup of 13 planned trials, with seven of them already in progress.
Clinical trials are currently being conducted on a wide range of prescription and over-the-counter drugs from various pharmacological groups. These include anticoagulants, antispasmodics, antihypoxants, antivirals, and many others. By 2025, Binnopharm Group aims to develop approximately 100 drugs, as stated by Aleksey Chupin, the Director for Development and Registration. This ambitious goal is set to be achieved with the establishment of the upcoming R&D center, whose opening is scheduled for this year.
